Question 1

Why can generic IV drugs be bioequivalent to branded drugs despite stability differences?

Accepted Answer

Generic IV products are considered bioequivalent because they achieve 100% bioavailability upon administration, meeting pharmaceutical equivalence criteria. However, stability can vary between drug products, potentially affecting therapeutic performance even when chemical composition is identical. This distinction is critical when evaluating whether generic and branded drugs will perform equally in clinical settings.

Question 2

What happened when generic cefuroxime was substituted for branded cefuroxime in surgical prophylaxis?

Accepted Answer

When generic cefuroxime replaced branded cefuroxime for surgical infection prevention, post-surgical infection rates increased significantly, with some patients requiring intensive care. Investigations revealed the generic product underwent rapid hydrolysis, reducing its effectiveness by administration time despite chemical equivalence. Reintroducing the branded drug decreased severe infections, confirming the generic's stability deficiency caused therapeutic failure.

Question 3

How can two chemically identical drugs have different therapeutic outcomes?

Accepted Answer

Stability differences between formulations can cause chemically identical drugs to perform differently clinically. The generic cefuroxime case demonstrates this: despite identical chemical composition, rapid hydrolysis degraded the generic product before administration, reducing serum levels below therapeutic thresholds. Differences in formulation or manufacturing processes likely caused this stability variation, highlighting that chemical equivalence alone does not guarantee therapeutic equivalence.

Question 4

What role does drug stability play in pharmaceutical nonequivalence?

Accepted Answer

Stability-related issues are a major contributor to pharmaceutical nonequivalence, particularly in IV products. Even when generic and branded drugs meet pharmaceutical equivalence criteria, variations in stability can significantly influence therapeutic performance. Rapid degradation through hydrolysis or other mechanisms reduces drug concentration at the site of action, potentially causing treatment failure despite initial chemical equivalence.

Question 5

Why might manufacturing process differences affect drug stability?

Accepted Answer

Manufacturing process differences can influence how drugs are formulated, affecting their resistance to degradation. The generic cefuroxime case suggests that variations in manufacturing led to increased susceptibility to hydrolysis compared to the branded version. These process-related differences may involve excipient selection, pH control, or storage conditions that either protect or expose the active ingredient to degradation pathways.

Question 6

What dosing regimen was used for cefuroxime surgical prophylaxis?

Accepted Answer

Cefuroxime surgical prophylaxis typically involves a 3 g single-dose IV injection before anesthetic induction to achieve sufficient serum levels for infection prevention during surgery. An additional 0.75 g dose is administered 12 hours post-surgery to maintain protection. This regimen depends on the drug maintaining adequate stability and serum concentration throughout the perioperative period.

Question 7

How can stability issues be identified when comparing generic and branded drugs?

Accepted Answer

Stability issues emerge when clinical outcomes diverge despite pharmaceutical equivalence and 100% bioavailability. The cefuroxime case revealed stability problems through increased post-surgical infections with the generic product and their resolution upon switching back to branded drug. Investigating such clinical failures can identify rapid hydrolysis or other degradation mechanisms that compromise drug efficacy before administration.

Alternatywy farmaceutyczne: nieekwiwalencja terapeutyczna wynikająca z różnic w stabilności

Browse More Videos